{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:05:15Z","timestamp":1784293515396,"version":"3.55.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/100010398","name":"Metro South Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010398","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pathology Queensland","award":["5951_COSSART_STAATZ"],"award-info":[{"award-number":["5951_COSSART_STAATZ"]}]},{"name":"University of Queensland, School of Pharmacy"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Therapeutic monitoring is routinely performed to ensure tacrolimus whole-blood concentrations fall within a predefined target. Despite this, patients still experience inefficacy and toxicity that could be related to variability in free (unbound) tacrolimus exposure. Therefore, the aim of this study was to compare tacrolimus-free plasma (C<jats:sub>u<\/jats:sub>), total plasma (C<jats:sub>p<\/jats:sub>), and whole-blood (C<jats:sub>wb<\/jats:sub>) concentrations in adult kidney transplant recipients and to characterize tacrolimus disposition across different matrices.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Twelve-hour concentration\u2013time profiling was performed in 15 recipients, allowing simultaneous measurement of C<jats:sub>u<\/jats:sub>, C<jats:sub>p<\/jats:sub>, and C<jats:sub>wb<\/jats:sub>. Pharmacokinetic parameters were estimated using noncompartmental analysis. The relationship between C<jats:sub>wb<\/jats:sub> and C<jats:sub>p<\/jats:sub> were examined using a capacity-limited binding model, incorporating the hematocrit fraction (<jats:italic toggle=\"yes\">f<\/jats:italic>\n                                 <jats:sub>HCT<\/jats:sub>) to estimate maximum binding concentration (<jats:italic toggle=\"yes\">B<\/jats:italic>\n                                 <jats:sub>max<\/jats:sub>) and dissociation constant (<jats:italic toggle=\"yes\">K<\/jats:italic>\n                                 <jats:sub>\n                                    d\n                                 <\/jats:sub>). The relationship between C<jats:sub>p<\/jats:sub> and C<jats:sub>u<\/jats:sub> was evaluated using a linear binding model to estimate the nonspecific binding parameter (<jats:italic toggle=\"yes\">N<\/jats:italic>\n                                 <jats:sub>\n                                    plasma\n                                 <\/jats:sub>). Nonlinear regression analysis was used to obtain estimates of <jats:italic toggle=\"yes\">B<\/jats:italic>\n                                 <jats:sub>max<\/jats:sub>, <jats:italic toggle=\"yes\">K<\/jats:italic>\n                                 <jats:sub>\n                                    d\n                                 <\/jats:sub>, and <jats:italic toggle=\"yes\">N<\/jats:italic>\n                                 <jats:sub>\n                                    plasma\n                                 <\/jats:sub>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 195 paired C<jats:sub>wb<\/jats:sub>, C<jats:sub>p<\/jats:sub>, and C<jats:sub>u<\/jats:sub> values were collected. The median ratios of C<jats:sub>wb<\/jats:sub>:C<jats:sub>p<\/jats:sub>, C<jats:sub>p<\/jats:sub>:C<jats:sub>u<\/jats:sub>, and C<jats:sub>wb<\/jats:sub>:C<jats:sub>u<\/jats:sub> were 9:1, 20:1, and 138:1, respectively. Variability in free plasma exposure was large; free trough values ranged from 8 to 51 ng\/L and free area-under-the-concentration\u2013time-curve values ranged from 424 to 7160 ng\u00b7h\/L. Median (range) estimates of <jats:italic toggle=\"yes\">B<\/jats:italic>\n                                 <jats:sub>max<\/jats:sub>, <jats:italic toggle=\"yes\">K<\/jats:italic>\n                                 <jats:sub>\n                                    d\n                                 <\/jats:sub>, and <jats:italic toggle=\"yes\">N<\/jats:italic>\n                                 <jats:sub>\n                                    plasma\n                                 <\/jats:sub> were 90.4 \u00b5g\/L (22.4\u2013752.5 \u00b5g\/L), 2.36 \u00b5g\/L (0\u201369.2 \u00b5g\/L), and 0.05 (0.035\u20130.085), respectively. The interindividual variability (CV%) in binding parameters was considerable (<jats:italic toggle=\"yes\">B<\/jats:italic>\n                                 <jats:sub>max<\/jats:sub> 117.2%; <jats:italic toggle=\"yes\">N<\/jats:italic>\n                                 <jats:sub>\n                                    plasma\n                                 <\/jats:sub> 32.5%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Large variability was observed in tacrolimus-free plasma exposure and binding parameters. Future research to characterize the relationship between tacrolimus C<jats:sub>u<\/jats:sub> and patient outcomes may be of benefit.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001274","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:01:20Z","timestamp":1731002480000},"page":"161-168","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Examining Whole Blood, Total and Free Plasma Tacrolimus in Elderly Kidney Transplant Recipients"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4032-6657","authenticated-orcid":false,"given":"Amelia R.","family":"Cossart","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Queensland, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Isbel","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott B.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"McWhinney","sequence":"additional","affiliation":[{"name":"Chemical Pathology, Pathology Queensland, Herston Hospitals Complex, Brisbane, QLD, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Queensland, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"717148","DOI":"10.3389\/fphar.2021.717148","article-title":"Case report: low hematocrit leading to tacrolimus toxicity","volume":"12","author":"Piletta-Zanin","year":"2021","journal-title":"Front Pharmacol."},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1440-1797.2011.01559.x","article-title":"KHA-CARI guideline: KHA-CARI adaptation of the KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"17","author":"Chadban","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"635165","DOI":"10.3389\/fphar.2021.635165","article-title":"Pharmacokinetic and pharmacodynamic considerations in relation to calcineurin usage in elderly kidney transplant recipients","volume":"12","author":"Cossart","year":"2021","journal-title":"Front Pharmacol."},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-198712010-00004","article-title":"Plasma protein binding of drugs in the elderly","volume":"12","author":"Wallace","year":"1987","journal-title":"Clin Pharmacokinet."},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bcp.12361","article-title":"Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling","volume":"78","author":"St\u00f8rset","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","article-title":"Population pharmacokinetic modelling and bayesian estimation of tacrolimus exposure: is this clinically useful for dosage prediction yet?","volume":"55","author":"Brooks","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin Pharmacol Ther."},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40262-019-00854-1","article-title":"Unbound plasma, total plasma, and whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation","volume":"59","author":"Sikma","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00007691-200410000-00008","article-title":"Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation","volume":"26","author":"Zahir","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40262-019-00846-1","article-title":"Clinical pharmacokinetics and impact of hematocrit on monitoring and dosing of tacrolimus early after heart and lung transplantation","volume":"59","author":"Sikma","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1136\/ejhpharm-2018-001663","article-title":"Retrospective analysis of the correlation between tacrolimus concentrations measured in whole blood and variations of blood cell counts in patients undergoing allogeneic haematopoietic stem cell transplantation","volume":"27","author":"Yoshikawa","year":"2020","journal-title":"Eur J Hosp Pharm."},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/TP.0000000000000708","article-title":"Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients\u2014A prospective, randomized study","volume":"99","author":"St\u00f8rset","year":"2015","journal-title":"Transplantation"},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"956389","DOI":"10.1155\/2015\/956389","article-title":"Effects of storage temperature and time on stability of serum tacrolimus and cyclosporine A levels in whole blood by LC-MS\/MS","volume":"2015","author":"Kaplan","year":"2015","journal-title":"Int J Anal Chem."},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"St\u00f8rset","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1056-8719(02)00158-2","article-title":"Validation of methods to study the distribution and protein binding of tacrolimus in human blood","volume":"46","author":"Zahir","year":"2001","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FTD.0000000000000392","article-title":"Simultaneous determination of protein-unbound cyclosporine A and mycophenolic acid in kidney transplant patients using liquid chromatography\u2013tandem mass spectrometry","volume":"39","author":"Bittersohl","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R20-20250108","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/bdd.2510140803","article-title":"Distribution characteristics of Immunosuppressants FK506 and cyclosporin A in the blood compartment","volume":"14","author":"Takada","year":"1993","journal-title":"Biopharm Drug Dispos"},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.2042-7158.1994.tb03752.x","article-title":"Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes","volume":"46","author":"Nagase","year":"1994","journal-title":"J Pharm Pharmacol."},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40262-020-00959-y","article-title":"Clinical pharmacokinetics and bayesian estimators for the individual dose adjustment of a generic formulation of tacrolimus in adult kidney transplant recipients","volume":"60","author":"Marquet","year":"2021","journal-title":"Clin Pharmacokinet."},{"key":"R23-20250108","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00007691-199508000-00074","article-title":"Comparison between whole blood tacrolimus by Abbott IMx and plasma tacrolimus by Enzyme-linked immunoassay","volume":"17","author":"Warty","year":"1995","journal-title":"Ther Drug Monit."},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/ki.1983.110","article-title":"Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis","volume":"23","author":"Bergrem","year":"1983","journal-title":"Kidney Int."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:01:29Z","timestamp":1736348489000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001274","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"2022-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}